CADTH Canadian Drug Expert Committee recommendation: Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) indication : treatment of neovascular (wet) age-related macular degeneration (nAMD)
Brolucizumab has a Health Canada indication for the treatment of nAMD. Brolucizumab is a humanized monoclonal single-chain Fv (scFv) antibody fragment directed against human VEGF. It is available as a single-use pre-filled syringe for intravitreal injection and the Health Canada-approved dose is 6 m...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, May 2020
|
| Edition: | Version: 1 |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Brolucizumab has a Health Canada indication for the treatment of nAMD. Brolucizumab is a humanized monoclonal single-chain Fv (scFv) antibody fragment directed against human VEGF. It is available as a single-use pre-filled syringe for intravitreal injection and the Health Canada-approved dose is 6 mg (0.05 mL) administered by intravitreal injection every four weeks for the first three doses, after which it can be given as one injection every 12 weeks in patients without disease activity or one injection every eight weeks in patients with disease activity, based on the physician assessment |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (8 pages) |